Investorplace.comA Big Bet on Gene Therapy Is Just What Novartis AG (ADR) Stock NeedsInvestorplace.comRespectfully, patients suffer from the disease but the potential revenue for treatment is limited. The hope for investors is that the clinical studies… Continue reading
Medical XpressDrug combination overcomes barrier to effective melanoma immunotherapyMedical XpressImmunotherapies stimulate the CD8 T cells to attack tumors more vigorously. But the activity of CD8 T cells can be suppressed by other immune cells presen… Continue reading
MesotheliomaHelp.org (blog)Combination Immunotherapy Treatment for Mesothelioma “Significantly Prolonged Survival”MesotheliomaHelp.org (blog)Two drugs are often better than one for mesothelioma patients, with a combination of the chemotherapy drugs cis… Continue reading
|
Novartis’ $8.7bn AveXis deal shows gene therapy appeal
Chemistry World This is Novartis’ second deal related to an AAV-based gene therapy. In January, it licensed marketing rights for Luxturna from Philadelphia, US-based Spark Therapeutics for $105 million up front and up to $65 million in milestone payments. In December … Worldwide Cancer Gene Therapy Market Overview, Region Wise Analysis of Top Players and Feasibility Studies 2023Pharmaceuticals News Cancer Gene Therapy Market to Record an Exponential CAGR by 2025The Columnist |
Technology Networks |
Lonza Opens World’s Largest Dedicated Cell-and-Gene–Therapy Manufacturing Facility in Texas
Technology Networks … committed to the evolution and cultivation of a diverse medical and life-science community in the Greater Houston area for many years to come,” says Marc Funk, Lonza Pharma & Biotech Chief Operating Officer. “The site is well positioned to meet the … |